Breast cancer is the most common type of cancer and the leading cause of cancer-related mortality in women worldwide [1]. Dura-based metastasis occurs in 10% of breast cancer patients [2]. Meningioma is the most common primary intracranial neoplasm with a clear female predisposition, and a  2.3:1 female-to-male ratio [3]. Meningioma is typically a benign tumor (ie, benign in 98% of patients; grade one in 80% of patients; grade two, in 18.3% of patients; and grade three in 1.6% of patients), with a peak incidence from ages 50 to 70 years [4].

A recent meta-analysis of 18 retrospective studies has suggested that there is a strong association between breast cancer and meningioma. Breast cancer patients are more likely to develop meningioma, odds during the lifetime increased by 1.42-fold compared to the general population, and the risk is higher in younger patients and those with a more advanced tumor stage [5]. At the same time, patients with meningioma are at higher risk of developing breast cancer, 10-fold higher odds compared with the general female population [5]. A possible explanation of this association between the two tumors is hormone dependency: 88% of meningiomas express progesterone receptors, 30% express estrogen receptors; 50% of breast cancer express progesterone receptors, and 70% express estrogen receptors [5].  At the same time, there are several case reports describing breast cancer metastasis to meningiomas (tumor-to-tumor metastasis), the concern should be brought up in patients with a known history of coexisting breast cancer and meningioma presenting with new neurological symptoms [6].